Tower Research Capital (TRC)’s CytoMed Therapeutics GDTC Stock Holding History

Tower Research Capital (TRC)’s Portfolio GDTC Stock Details GDTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-13	Closed	-$28	–	5798
2024 Q1	$28	Sell	13 -869	-99%	-$2.55K	﹤0.01%	5741
2023 Q4	$4.32K	Buy	+882	New	+$3.32K	﹤0.01%	4968

Tower Research Capital (TRC)'s GDTC Position: Q2 2024 in Review

Tower Research Capital (TRC) sold out of CytoMed Therapeutics (GDTC) in Q2 2024, closing a stake of 13 shares — an estimated $28 sold.

Tower Research Capital (TRC) first reported a position in GDTC in Q4 2023 and held it in 2 quarters. The position peaked at $4.32K in Q4 2023. 0 funds tracked by Wall St. Rank hold GDTC as of Q2 2024.

Tower Research Capital (TRC) reported no remaining CytoMed Therapeutics position as of Q2 2024 after selling out during the quarter.
Tower Research Capital (TRC) sold 13 CytoMed Therapeutics shares in Q2 2024, an estimated $28.
Tower Research Capital (TRC) first reported a position in CytoMed Therapeutics in Q4 2023 and held it in 2 quarters.
Tower Research Capital (TRC)'s CytoMed Therapeutics position peaked at $4.32K in Q4 2023.
0 funds tracked by Wall St. Rank held CytoMed Therapeutics as of Q2 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2024, filed 13 Aug 2024.